Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Inclusion Criteria:

• Participants with histologically or cytologically confirmed advanced or metastaticovarian, CRPC, HR+ HER2- breast, endometrial, colorectal, small-cell lung, orpancreatic cancer, who have progressed following standard-of-care therapy or for whomthere is no standard therapy that confers clinical benefit
• Measurable disease per RECIST v 1.1
• ECOG performance status 0,1 or 2
• Life expectancy of at least 3 months
• Age ≥ 18 years
• Signed, written IRB-approved informed consent form

Exclusion Criteria:

• New York Heart Association Class III or IV cardiac disease, or myocardial infarction,severe unstable angina, coronary/peripheral artery bypass graft, congestive heartfailure within the past 6 months
• Have a corrected QT interval (using Fridericia's correction formula) (QTcF) of >470msec (females) and >450 msec (males)
• Active, uncontrolled bacterial, viral, or fungal infections, requiring systemictherapy
• Active, poorly controlled autoimmune or inflammatory diseases